Congenital toxoplasmosis in the United Kingdom: To screen or not to screen?

Journal of Medical Screening

Volumn 9, Issue 3, 2002, Pages 135-141

  Gilbert, Ruth E ^a   Peckham, C S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CONGENITAL TOXOPLASMOSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; NEWBORN SCREENING; PREGNANCY; PRENATAL SCREENING; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; UNITED KINGDOM;

DISEASE TRANSMISSION, VERTICAL; FEMALE; FETAL DISEASES; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MASS SCREENING; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; TOXOPLASMOSIS, CONGENITAL;

EID: 0036400616     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1136/jms.9.3.135     Document Type: Review

References (62)

1. Working Group on Toxoplasma Infection in Pregnancy. Antenatal and newborn screening for toxoplasmosis. Antenatal subcammittee, National Screening Committee 2001. http://www.nelh.nhs.uk/screening/antenatal_pps/toxoplasmosis.html (accessed 26/07/02).
2. Remington JS, McLeod R, Thulliez P, et al. Toxoplasmosis. In: Remington JS, Klein J, eds. Infectious diseases of the fetus and newborn infant, 5th ed. Philadelphia: WB Saunders, 2001:205-346.
3. Cook AC, Gilbert RE, Buffolano W, et al. Sources of infection in pregnant women: a European multicentre case-control study. BMJ 2000;321:142-7.
4. Thulliez P. Screening programme for congenital toxoplasmosis in France. Scand J Infect Dis Suppl 1992;84:43-5.
5. Raeber PA, Biedermann K, Just M, et al. Prevention of congenital toxoplasmosis in Europe. Schweiz Med Wochenschr Suppl 1995;65:96S-102S.
6. Buffolano W, Sagliocca L, Fratta D, et al. Prenatal toxoplasmosis screening in campania region, italy. Ital J Gynaecol Obstet 1994;6:70-4.
7. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001;127:113-20.
8. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
9. Lebech M, Andersen O, Christensen CN, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 1999;353:1834-7.
10. Ancelle T, Goulet V, Tirard-Fleury V, et al. La Toxoplasmose chez la femme enceinte en France en 1995. Resultats d'une enquete nationale perinatale. Bulletin Epidemiotogique Hebdomadiare 1996;51:227-9.
11. Guimaraes AC, Kawarabayashi M, Borges MM, et al. Regional variation in toxoplasmosis seronegativity in the Sao Paulo metropolitan region. Rev Inst Med Trop Sao Paulo 1993;35:479-83.
12. Ades AE, Nokes DJ. Modeling age and time specific incidence from seroprevalence: toxoplasmosis. Am J Epidemiol 1993;137:1022-34.
13. Gilbert RE. Epidemiology of infection in pregnant women. In: Petersen E, Amboise-Thomas P, eds. Congenital toxoptasmosis: scientific background, clinical management and control, 1st ed. Paris: Springer-Verlag, 2000.
14. Evengard B, Petterson K, Engman M-L, et al. Low incidence of toxoplasma infection during pregnancy and in newborns in Sweden. Epidemiol Infect 2001;127:121-7.
15. Neto EC, Anele E, Rubim R, et al. High prevalence of congenital toxoplasmosis in Brazil estimated in a 3 year prospective neonatal screening study. Int J Epidemiol 2000;29:941-7.
16. Ades AE. Methods for estimating the incidence of primary infection in pregnancy: a reappraisal of toxoplasmosis and cytomegalovirus data. Epidemiol Infect 1992;10B:367-75.
17. Gras L, Gilbert RE, Wallon M, et al. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001;30:1309-30.
18. Koppe JG, Loewer Sieger DH, de Roever Bonnet H. Results of 20 year follow up of congenital toxoplasmosis. Lancet 1986;i:254-6.
19. Conyn-van-Spaedonck MAE. Prevention of congenital toxoplasmosis in the Netherlands [thesis]. Bilthoven: National Institute of Public Health and Environmental Protection 1991;ISBN 90-9004179-6.
20. Lappalainen M, Koskiniemi M, Hiilesmaa V, et al. Outcome of children after maternal primary Toxoplasma infection during pregnancy with emphasis on avidity of specific IgG. The Study Group. Pediatr Infect Dis J 1995;14:354-61.
21. Dunn D, Wallon M, Peyron F, et al. Mother to child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999;353:1829-33.
22. Jenum PA, Stray Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997;35:1972-7.
23. Roberts A, Hedman K, Luyasu V, et al. Primary infection with Toxoplasma gondii: a multicentre study of serological diagnosis. Eur J Clin Microbiol 1999. 2001;20:467-74.
24. Romand S, Wallon M, Franck J, et al. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2007;97:296-300.
25. Berrebi A, Kobuch WE, Bessieres MH, et al. Termination of pregnancy for maternal toxoplasmosis. Lancet 1994;344:36-9.
26. Hohlfeld P, MacAleese J, Capella-Pavlovsky M, et al. Fetal toxoplasmosis: ultrasonographic signs. Ultrasound Obstet Gynecol 1991;1:241-4.
27. McCabe RE. Antitoxoplasma chemotherapy. In: Joynson DHM, Wreghitt TG, eds. Toxoplasmosis: a comprehensive clinical guide, 1st ed. Cambridge: Cambridge University Press, 2001:319-59
28. Wallon M, Liou C, Garner P, et al. Congenital toxoplasmosis: what is the evidence that treatment in pregnancy prevents congenital disease? BMJ 1999;318:1511-4.
29. Eskild A, Oxman A, Magnus Per, et al. Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? J Med Screen 1996;3:188-94.
30. Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis: effects of spiramycin an placental infection. J Antimicrob Chemother 1988;22(suppl B):193-200.
31. Gilbert RE, Gras L, Wallon M, et al. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: a cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 2001;30:1303-8.
32. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicentre study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999;180:410-5.
33. Schoondermark van de Yen E, Melchers W, Galama J, et al. Congenital toxoplasmosis: an experimental study in rhesus monkeys for transmission and prenatal diagnosis. Exp Parasitol 1993;77:200-11.
34. Derouin F. Drugs effective against Toxoplasma gondii. Present status and future perspective. In: Amboise-Thomas P, Petersen E, eds. Congenital toxoplasmosis: scientific background, clinical management, and control, 1st ed. Paris: Springer Verlag, 2000:95-110.
35. Luder CGK, Giraldo Velasquez MA, Sendtner M, et al. Toxoplasma gondii in primary rat CNS cells: differential contribution of neurons, astrocytes, and microglial cells for the intracerebral development and stage differentiation. Exp Parasitol 1999;93:23-32.
36. Sahm M, Fischer H-G, Gross U, et al. Cyst formation by toxoplasma gondii in vivo and in brain-cell culture: a comparative morphology and immunocytochemistry study. Parasitol Res 1997;83:659-65.
37. Roberts F, McLeod R. Pathogenesis of toxoplasmic retinochoroiditis. Parasitol Today 1999;15:51.
38. Lebech M, Joynson DH, Seitz HM, et al. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. Eur J Clin Microbiol Infect Dis 1996;15:799-805.
39. Wallon M, Dunn D, Slimani D, et al. Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA? Eur J Pediatr 1999;158:645-9.
40. Bucher HC, Griffith L, Guyatt GH, et al. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV infected patients. Journal of the Acquired Immune Deficiency Syndrome and Human Retrovirology 1997;15:104-14.
41. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992;116:33-43.
42. Frenkel JK. Biology of Toxoplasma gondii. In: Amboise-Thomas P, Petersen E, eds. Congenital toxoplasmosis: scientific background, clinical management and control, 1st ed. Paris: Springer-Verlag, 2000:9-25.
43. Guy EC, Pelloux H, Lappalainen M, et al. Interlaboratory comparison of polymerase chain reaction for the detection of Toxoplasma gondii DNA added to samples of amniotic fluid. Eur J Clin Microbiol Infect Dis 1996;15:836-9.
44. Petithory JC, Reiterowona I, Berthelot F, et al. Performance of European laboratories testing serum samples for Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 1996;15:45-9.
45. Liesenfeld O, Montoya JG, Tathineni NJ, et al. Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am J Obstet Gynecol 2001;184:140-5.
46. Paul M, Petersen E, Pawlowski ZS, et al. Neonatal screening for congenital toxoplasmosis in the Poznan region of Poland by analysis of Toxoplasma gondii-specific IgM antibodies eluted from filter paper blood spots. Pediatr Infect Dis J 2000;19:30-6.
47. Mombro M, Perathoner C, Leone A, et al. Congenital toxoplasmosis: 10 year follow up. Eur J Pediatr 1995;154:635-9.
48. Kieffer F, Thulliez P, Brezin A, et al. Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases. Arch Pediatr 2002;9:7-13.
49. Stramba-Badiale M, Nador F, Porta N, et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 1997;133:108-11.
50. Lappalainen M, Sintonen H, Koskiniemi M, et al. Cost-benefit analysis of screening for toxoplasmosis during pregnancy. Scand J Infect Dis 1995;27:265-72.
51. Roberts T, Frenkel JK. Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J Am Vet Med Assoc 1990;196:249-56.
52. Henderson JB, Beattie CP, Hale EG, et al. The evaluation of new services: possibilities for preventing congenital toxoplasmosis. Int J Epidemiol 1984;13:65-72.
53. Thorp JM Jr, Seeds JW, Herbert WNP, et al. Prenatal management and congenital toxoplasmosis. N Engl J Med 1988;319:372-3.
54. Bader TJ, Macones GA, Asch DA. Prenatal screening for toxoplasmosis. Obstet Gynecol 1997;90:457-64.
55. Gilbert RE, Augood C, Gupta R, et al. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423-5.
56. Peyron F, Wallon M. Options for the pharmacotherapy of toxoplasmosis during pregnancy. Expert Opinions on Pharmacotherapy 2001;2:1269-74.
57. Wallon M, Mallaret MR, Mojon M, et al. Congenital toxoplasmosis, evaluation of the prevention policy. Presse Med 1994;23:1467-70.
58. Kapperud G, Jenum PA, Stray Pedersen B, et al. Risk factors for Toxoplasma gondii infection in pregnancy: results of a prospective case-control study in Norway. Am J Epidemiol 1996;144:405-12.
59. Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection. Br J Ophthalmol 2000;84:224-6.
60. Bowie WR, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. Lancet 1997;350:173-7.
61. Lappalainen M, Koskela P, Hedman K, et al. Incidence of primary toxoplasma infections during pregnancy in southern Finland: a prospective cohort study. Scand J Infect Dis 1992;24:97-104.
62. Jenum PA, Stray Pedersen B, Melby KK, et al. Incidence of Toxoplasma gondii infection in 35 940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol 1998;36:2900-6.